MedTrace Logo

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

NCT01511510 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2019-11-21

No results posted yet for this study

Summary

This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of ascending doses administered once daily for 14 days in healthy volunteers.

Conditions

Interventions

DRUG

PF-04958242

PF-04958242 0.05 mg oral solution Q24 hours for 14 days

DRUG

PF-04958242

PF-04958242 0.10 mg oral solution Q24 hours for 14 days

DRUG

PF-04958242

PF-04958242 0.15 mg oral solution Q24 hours for 14 days

DRUG

PF-04958242

PF-04958242 0.25 mg oral solution Q24 hours for 14 days

DRUG

Placebo

Placebo oral solution Q24 hours for 14 days

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01511510 on ClinicalTrials.gov